The 4TAZPower study will follow participants with Barth syndrome for 72 weeks to assess the efficacy and safety.
Patients may not know that these treatments are experimental or about the risks they may pose. The latest in AJC's ...
"I asked the world's top ageing scientists what actually works. They kept giving me the same unglamorous answer." ...
A 76-year-old man presented with a 3-week history of binocular vertical diplopia.He denied change in vision, pain with eye ...
Incyte Corporation (NASDAQ:INCY) on Monday reported complete Phase 1/2 multidose data for latarcibart (VGA039), showing ...
Industry-leading compounding pharmacy introduces Methylcobalamin, Glutathione, and Magnesium Chloride to support cellular energy, metabolic health, and antioxidant defenseORLANDO, Fla., June 23, 2026 ...
A distributed “hub-and-spoke” operation could register as one establishment, reducing administrative friction while improving ...
The 2009 Cadillac CTS-V packs a 556 hp supercharged LSA V8 shared with the Corvette, with bulletproof reliability at a ...
Pharmaceutical Technology on MSN
European Commission approves Novartis’ Itvisma to treat SMA
The approval is supported by data from the STEER, Phase IIIb STRENGTH and Phase I/II STRONG studies.
Court TV on MSN
Doctor charged with killing wife during liposuction fights medical examiner’s testimony
Dr. Benjamin Brown has pleaded not guilty to manslaughter in the death of his wife, who was undergoing cosmetic procedures ...
Discover 5 of the best-looking Ford restomods. We review the GT40 MKII, Bronco, Mustang GT500CR Carbon, Escort Mk1 RS, and ...
Cemdisiran, a potential new drug for the treatment of generalized myasthenia gravis, has been accepted for priority review by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results